AIMS: Ionic perturbation in vascular smooth muscle cells contributes to @entity5707 in the setting of @entity101 , but the role of transient receptor potential (TRP) channel superfamily remains unknown. The present study was conducted to define the contribution of TRP channels to @entity5707 . METHODS AND RESULTS: By integrating quantitative PCR, western blotting, patch clamping, and @entity141 imaging, we identified TRP channel, subfamily canonical, member 3 ( @entity58919 ) as the channel subtype most considerably elevated in basilar arteries of two-kidney, two-clip @entity64 -prone @entity101 @entity35 . Importantly, administration of @entity12905 3 (Pyr3), a @entity58919 channel blocker, @entity536 . During @entity101 , @entity10816 ( @entity10816 ) was transactivated, as evidenced by marked @entity10816 phosphorylation, increased pro- @entity33357 shedding, and elevated activity of @entity30469 ( @entity33357 sheddase). @entity30469 activity was increased owing to enhanced activation rather than elevated expression. Remarkably, Pyr3 treatment suppressed @entity10816 transactivation in @entity101 . In proliferating basilar artery smooth muscle cells or basilar arteries of @entity101 @entity35 , co-immunoprecipitation assay revealed an interaction between @entity58919 and @entity30469 upon Ang II stimulation. CONCLUSION: Collectively, we demonstrated that enhanced @entity10816 transactivation, due to increased @entity58919 expression and functional coupling of @entity58919 / @entity30469 , resulted in @entity5707 . Therefore, @entity58919 -induced @entity10816 transactivation may be therapeutically exploited to prevent @entity101 -induced @entity5707 .

@entity58919 channel confers @entity5707 during XXXX via transactivation of EGF receptor signalling.

@entity64 :: ('MESH:D020521', 'Disease') :: ['stroke'] @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension', 'hypertensive'] @entity35 :: ('10116', 'Species') :: ['rats'] @entity10816 :: ('24329(Tax:10116)', 'Gene') :: ['EGFR', 'epidermal growth factor receptor'] @entity536 :: ('MESH:C538265', 'Disease') :: ['attenuated cerebrovascular remodelling'] @entity58919 :: ('60395(Tax:10116)', 'Gene') :: ['TRPC3'] @entity5707 :: ('MESH:D020257', 'Disease') :: ['cerebrovascular remodelling'] @entity141 :: ('CHEBI:29108', 'Chemical') :: ['Ca(2+)'] @entity30469 :: ('57027(Tax:10116)', 'Gene') :: ['ADAM17'] @entity33357 :: ('25433(Tax:10116)', 'Gene') :: ['HB-EGF'] @entity12905 :: ('MESH:C031280', 'Chemical') :: ['pyrazole']
@entity101 :: (MESH:D006973,Disease) :: ['hypertension']
